133 related articles for article (PubMed ID: 33550876)
21. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
22. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
23. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
24. Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification.
Connors JM
Cancer J; 2018; 24(5):230-236. PubMed ID: 30247258
[TBL] [Abstract][Full Text] [Related]
25. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE; Girinsky T; Federico M; Reman O; Fortpied C; Gotti M; Casasnovas O; Brice P; van der Maazen R; Re A; Edeline V; Fermé C; van Imhoff G; Merli F; Bouabdallah R; Sebban C; Specht L; Stamatoullas A; Delarue R; Fiaccadori V; Bellei M; Raveloarivahy T; Versari A; Hutchings M; Meignan M; Raemaekers J
J Clin Oncol; 2017 Jun; 35(16):1786-1794. PubMed ID: 28291393
[TBL] [Abstract][Full Text] [Related]
26. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
27. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Cochrane T; Campbell BA; Gangatharan SA; Latimer M; Khor R; Christie DRH; Gilbertson M; Ratnasingam S; Palfreyman E; Lee HP; Trotman J; Hertzberg M; Dickinson M
Intern Med J; 2021 Dec; 51(12):2119-2128. PubMed ID: 34505342
[TBL] [Abstract][Full Text] [Related]
28. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
29. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
Terasawa T; Nagai H
Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET for Early Response Assessment in Lymphomas: Part 1-Hodgkin Lymphoma.
Cheson BD; Kostakoglu L
Oncology (Williston Park); 2017 Jan; 31(1):45-9. PubMed ID: 28090622
[TBL] [Abstract][Full Text] [Related]
31. Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.
Lynch RC; Advani RH
Am Soc Clin Oncol Educ Book; 2016; 35():e376-85. PubMed ID: 27249744
[TBL] [Abstract][Full Text] [Related]
32. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
33. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans.
Picardi M; De Renzo A; Pane F; Nicolai E; Pacelli R; Salvatore M; Rotoli B
Leuk Lymphoma; 2007 Sep; 48(9):1721-7. PubMed ID: 17786707
[TBL] [Abstract][Full Text] [Related]
34. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
35. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
36. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.
Nagai H
Jpn J Clin Oncol; 2015 Feb; 45(2):137-45. PubMed ID: 25489004
[TBL] [Abstract][Full Text] [Related]
38. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years.
Vassilakopoulos TP; Angelopoulou MK
Semin Hematol; 2013 Jan; 50(1):4-14. PubMed ID: 23507479
[TBL] [Abstract][Full Text] [Related]
39. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
Zinzani PL; Broccoli A; Gioia DM; Castagnoli A; Ciccone G; Evangelista A; Santoro A; Ricardi U; Bonfichi M; Brusamolino E; Rossi G; Anastasia A; Zaja F; Vitolo U; Pavone V; Pulsoni A; Rigacci L; Gaidano G; Stelitano C; Salvi F; Rusconi C; Tani M; Freilone R; Pregno P; Borsatti E; Sacchetti GM; Argnani L; Levis A
J Clin Oncol; 2016 Apr; 34(12):1376-85. PubMed ID: 26884559
[TBL] [Abstract][Full Text] [Related]
40. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
